Contents

Search


besifloxacin (Besivance)

Indications: - eye infection - bacterial conjunctivitis - corneal ulcers [3] Contraindications: - pregnancy category: C Dosage: - one drop affected eye(s) TID for & days Suspension: 0.6% Storage: 15-25 C; protect from light Antimicrobial activity: - gram-positive bacteria - CDC coryneform group G - Corynebacterium pseudodiphtheriticum - Corynebacterium striatum - Staphylococcus aureus - Staphylococcus epidermidis, - Staphylococcus hominis - Staphylococcus lugdunensis - Streptococcus mitis group, - Streptococcus oralis - Streptococcus pneumonia, - Stretococcus salivarius - gram-negative bacteria - Haemophilus influenzae - Moraxella Lacunata, Adverse effects: - uuncommon, reported in < 3% of patients - blurred vision - eye pain & redness - irritation & itching - headache Complications: - overgrowth of nonsusceptible organisms, including fungi especially with prolonged use Mechanism of action: - inhibits both bacterial DNA gyrase & topoisomerase IV

Interactions

drug adverse effects of fluoroquinolones

Specific

Besifloxacin Ophthalmic

General

fluoroquinolone

References

  1. FDA Approves Besivance to Treat Bacterial Conjunctivitis May 2009 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm162486.htm
  2. Prescriber's Letter 16(7): 2009 New Drug: Besivance (Besifloxacin Ophthalmic Suspension 0.6%) Detail-Document#: 250722 (subscription needed) http://www.prescribersletter.com
  3. Deprecated Reference